Applications of (-)-Cis-2-Benzylaminocyclohexanemethanol in Industrial Manufacturing

As a core producer, we supply (-)-Cis-2-Benzylaminocyclohexanemethanol for advanced synthesis steps across multiple specialty chemical sectors. Its asymmetric structure supports precise chiral modifications that facilitate efficient transformation in regulated industrial processes. Our technical and quality control teams customize grades, documentation, and analytical support for each sector to ensure consistent performance in downstream integration.

1. Pharmaceutical Chiral Intermediate for Active Pharmaceutical Ingredients (APIs)

Pharmaceutical companies rely on this compound as a chiral building block during the synthesis of selective serotonin reuptake inhibitors (SSRIs), and other centrally acting agents where enantiomeric purity impacts therapeutic outcome. It enters early or mid-stage synthesis as a precursor for enantiomerically pure amine derivatives, supporting API projects requiring strict regulatory traceability. Our GMP-compliant production tracks each batch for audit, supply chain verification, and technical batch records, ensuring regulatory authorities’ validation.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.) 11th Edition
• United States Pharmacopeia (USP) standards for chiral intermediates
• FDA 21 CFR Part 211 for finished pharmaceuticals

Typical usage ratio

• 5–15% molar input relative to the targeted API backbone; ratio adjustment based on specific API structure and downstream yield optimization.

Downstream process integration

• Enters as a starting material in asymmetric hydrogenation, or reductive amination; processed under controlled temperature and closed systems to maintain chiral purity; immediate application into catalyst or resolution steps to control impurity profile.

Final product types

• Chiral pharmaceutical active ingredients (e.g., antidepressants, CNS therapeutics)
• Advanced pharmaceutical intermediates

2. Fine Chemical Synthesis for Agrochemical Active Compounds

Manufacturers integrate (-)-Cis-2-Benzylaminocyclohexanemethanol in the synthesis of optically active intermediates used for crop protection agents. Its chiral amine-alcohol functionality enables precise introduction of stereocenters in the synthesis of next-generation insecticides and herbicides. Agrochemical formulators maintain traceable documentation and batch integrity, adhering to strict ISO and national crop protection chemical regulations.

Industry compliance standards

• ISO 9001:2015 for quality management systems in chemical processing
• European Union Regulation (EC) No 1107/2009 concerning the placing of plant protection products on the market
• FAO/WHO JMPR specifications for pesticide raw materials
• REACH Regulation (EC 1907/2006) for registration, evaluation, authorization, and restriction of chemicals in the EU

Typical usage ratio

• 8–20% by weight relative to total precursor feedstock; specific ratio determined by target molecule and reaction efficiency.

Downstream process integration

• Utilized as a core intermediate during catalytic amination, followed by further derivatization for sulfonyl or heterocyclic agrochemical structures; addition typically occurs in the main reactor after completion of primary protection group cleavage.

Final product types

• Selective insecticide and fungicide active ingredients
• Chiral herbicide intermediates

3. Specialty Organic Synthesis for Advanced Materials R&D

Leading R&D departments use this chiral cyclohexanemethanol derivative in the development of new performance polymers and optically active materials. Its molecular scaffold enables the generation of high-purity monomers and molecular switches, critical for emerging electronics and high-value specialty plasticizers. Material development relies on correct stereochemistry and comprehensive supply documentation, reinforced by in-house analytical and quality systems.

Industry compliance standards

• ISO 9001:2015 certification in material science R&D
• RoHS Directive (EU) 2015/863 for hazardous substances in electrical and electronic equipment
• REACH compliance for advanced material precursors
• Customer-specified purity and enantiomeric excess standards

Typical usage ratio

• 10–25% w/w ratio in monomer mixtures; adjusted as per targeted polymer chain properties and trial batch parameters.

Downstream process integration

• Added after initial monomer synthesis, prior to condensation or ring-opening polymerization; role often as a co-monomer or as an initiator scaffold to induce desired chirality and flexibility in the final polymer.

Final product types

• Specialty polymers and co-polymers for electronics
• Chiral auxiliaries for molecular switches
• Optically active functional resins

4. Custom Synthesis in Contract Manufacturing (CMO/CDMO) Projects

Contract manufacturers (CMOs/CDMOs) in the pharmaceutical and specialty chemical sectors incorporate the compound for bespoke process development. Its defined stereochemistry and consistent supply support complex, multistep syntheses where chiral purity is critical. We provide comprehensive regulatory documentation, batch-specific certificates, and on-demand customization to meet client project specifications in line with contract manufacturing norms.

Industry compliance standards

• PIC/S Good Manufacturing Practice Guide for active ingredients
• ISO 13485 for medical device raw materials (when used in diagnostic intermediates)
• Client-specific quality and traceability documents (CoA, TSE/BSE declarations, stability data)
• Current Good Manufacturing Practice (CGMP) for intermediates in pharma custom synthesis

Typical usage ratio

• 5–12% of total process input, tailored per project protocol, molecular target, and required enantiopurity for the customer’s custom synthesis workflow.

Downstream process integration

• Deployed during multistep contract synthesis as an initial or mid-stage chiral input, often fed into hydrogenation, alkylation, or coupling reactions; quality and impurity profiling integrated at each process segment via in-line QC measures.

Final product types

• Targeted, customer-specified advanced intermediates
• Preclinical or clinical trial compounds for pharma and biotech
• Diagnostic chemical intermediates